Shawn Michael Chalifoux was indicted in February 2021 on charges including conspiracy to distribute 50 grams or more of methamphetamine and distribution of heroin, arising out of the Middle District of Florida. After pleading guilty to the conspiracy count, Chalifoux moved to withdraw his plea, and his counsel raised the question of his competency for the first time at the hearing on that motion. In February 2022, a magistrate judge appointed Dr. Randy K. Otto, Ph.D., to examine Chalifoux. Dr. Otto concluded that Chalifoux was unable to understand the nature of the consequences of the proceedings against him and assist properly in his defense as a result of a mental disorder — specifically, paranoid thinking. After a competency hearing in May 2022, a magistrate judge found him incompetent due to a delusional disorder and committed him to the custody of the Attorney General for treatment.
By September 2023, a Bureau of Prisons forensic psychologist reported that Chalifoux remained incompetent but that there was a substantial probability he could be restored to competency if the court authorized antipsychotic medication. The government then moved for a hearing under Sell v. United States, 539 U.S. 166 (2003), which permits involuntary medication of a mentally ill criminal defendant to render him competent if the government establishes four factors: an important government interest in prosecution, that involuntary medication would significantly further that interest, that it is necessary because less intrusive alternatives would not achieve the same result, and that it is medically appropriate.
At a May 2024 hearing before a magistrate judge, the government presented two expert witnesses — Dr. Sarah Burton and Dr. Shawn Rice — who both diagnosed Chalifoux with delusional disorder, persecutory type. Dr. Burton testified that Chalifoux had fixed false beliefs that were of a paranoid nature and that less intrusive treatments would not achieve the same results as medication because, in her view, no amount of talking or education would convince Chalifoux to think differently. Dr. Rice testified that antipsychotic medication would be "considered the first-line treatment for individuals with chronic severe psychotic mental illnesses" and that, while side effects were possible, many were manageable. Chalifoux's own expert, Dr. Richart DeMier, testified that he largely agreed with the government's experts, though he noted that Chalifoux had refused to speak with him on two occasions.
The magistrate judge issued a report and recommendation finding that the government had proven each Sell factor by clear and convincing evidence, describing the expert testimony as uncontroverted, and recommending that medication be administered and monitored in accordance with Dr. Rice's proposed treatment plan. The district court overruled Chalifoux's objections and adopted the recommendation. Chalifoux's principal objection on appeal — that he was not permitted to testify at the Sell hearing — fared no better. The Eleventh Circuit noted that Chalifoux never asked to testify until after the report and recommendation was prepared, and that he cited no authority for the proposition that the magistrate judge was required to raise the issue sua sponte, nor did he explain what he intended to testify about or how he was prejudiced.
On the merits, the panel reviewed the first Sell factor de novo and the remaining three for clear error, following United States v. Diaz, 630 F.3d 1314 (11th Cir. 2011). It held that the government's interest in prosecuting serious drug charges was important, that no special circumstances — such as extensive pretrial detention relative to the anticipated sentence, the prospect of civil commitment, or interference with an insanity defense — diminished that interest, and that the factual findings on the remaining three factors were not clearly erroneous given the detailed and uncontroverted expert record. The panel affirmed.